ALDX · XBRL financial data

Aldeyra Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (ALDX's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Research and development	6,962	4,298*	6,184	14,970	12,442	14,630*	7,423	8,505	5,431	4,304*	2,410	3,485
General and administrative	2,589	1,799*	3,210	3,038	3,696	1,948*	3,004	1,664	2,570	2,364*	1,137	2,366
Operating income (loss)	(9,550)	(6,098)*	(9,394)	(18,008)	(16,138)	(16,578)*	(10,427)	(10,169)	(8,001)	(6,668)*	(3,547)	(5,851)
Interest income	1,902	1,859*	1,810	1,638	1,504	1,240*	981	872	789	682*	563	400
Interest expense	539	514*	499	478	479	471*	484	471	476	475*	469	0
Income tax expense (benefit)	—	year only	—	—	—	year only	—	—	—	year only	—	—
Net income (loss)	(8,187)	(4,753)*	(8,082)	(16,848)	(15,113)	(15,809)*	(9,930)	(9,767)	(7,688)	(6,462)*	(3,453)	(5,450)
Earnings per share, basic USD per share	(0.14)	(0.08)*	(0.14)	(0.28)	(0.25)	(0.27)*	(0.17)	(0.16)	(0.13)	(0.11)*	(0.06)	(0.09)
Earnings per share, diluted USD per share	(0.14)	—	(0.14)	(0.28)	(0.25)	(0.27)*	(0.17)	(0.16)	(0.13)	(0.11)*	(0.06)	(0.09)
Weighted average shares, basic thousands of shares	58,990	59,194*	59,414	59,414	59,530	59,579*	59,887	60,046	60,127	60,163*	60,319	60,321
Weighted average shares, diluted thousands of shares	58,990	59,194*	59,414	59,414	59,530	59,579*	59,887	60,046	60,127	60,163*	60,319	60,321

Balance sheet

CSV

Fiscal quarters (ALDX's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	143,335	142,823	102,492	71,030	68,120	54,527	50,351	41,241	59,341	70,041	65,002	45,090
Marketable securities	0	0	30,545	49,302	44,624	46,624	39,707	40,678	15,957	0	—	—
Prepaid and other current assets	3,875	4,987	7,809	5,318	3,977	2,921	2,671	2,639	2,163	1,742	1,272	2,289
Total current assets	147,210	147,810	140,846	125,650	116,721	104,072	92,729	84,558	77,460	71,783	66,274	47,379
Property and equipment, net	8	6	4	3	1	0	—	—	—	0	—	21
Right-of-use asset	64	511	452	392	330	267	467	405	341	276	209	141
Total assets	147,282	148,327	141,302	126,044	117,319	104,607	93,196	84,963	77,801	72,059	66,483	47,541
Accounts payable	247	1,338	280	254	187	180	346	1,455	13	158	141	137
Accrued liabilities	7,843	5,536	5,944	5,843	10,423	12,118	7,684	6,664	6,999	6,120	2,672	3,374
Current portion of long-term debt	13,461	15,147	15,205	15,242	280	31	0	15,149	15,199	15,250	15,300	0
Total current liabilities	21,617	22,260	21,676	27,595	17,153	18,602	14,286	29,531	28,484	27,809	24,326	9,655
Long-term debt	2,657	0	0	0	15,000	15,000	15,099	0	0	0	0	—
Lease liability, non-current	—	272	206	139	70	0	213	143	73	0	0	0
Total liabilities	24,275	28,532	27,882	27,733	32,224	33,602	29,597	29,675	28,556	27,809	24,326	9,655
Accumulated deficit	(389,506)	(394,259)	(402,341)	(419,189)	(434,302)	(450,111)	(460,040)	(469,807)	(477,496)	(483,957)	(487,410)	(492,860)
Total stockholders' equity	123,008	119,795	113,419	98,310	85,096	71,005	63,599	55,288	49,245	44,250	42,157	37,885
Total liabilities and equity	147,282	148,327	141,302	126,044	117,319	104,607	93,196	84,963	77,801	72,059	66,483	47,541
Common shares outstanding (cover page) thousands of shares	58,822	58,896	59,414	59,422	59,550	59,709	59,896	59,896	60,163	60,183	60,321	60,326

Cash flows

CSV

Fiscal quarters (ALDX's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(8,187)	(4,753)*	(8,082)	(16,848)	(15,113)	(15,809)*	(9,930)	(9,767)	(7,688)	(6,462)*	(3,453)	(5,450)
Stock-based compensation	789*	(800)*	1,549	1,936*	3,226*	1,263*	2,224	197*	2,581*	1,090*	(988)	1,643*
Net cash from operating activities	(8,025)*	500*	(9,973)	(13,224)*	(7,975)*	(12,037)*	(12,470)	(8,555)*	(7,021)*	(5,299)*	(5,110)	(4,589)*
Purchases of property and equipment	0*	0*	—	—	—	—	—	—	—	—	—	—
Net cash from investing activities	0*	0*	(30,377)	(18,238)*	5,263*	(1,564)*	7,290	(554)*	25,000*	16,000*	0	(23)*
Net cash from financing activities	(316)*	(1,012)*	18	0*	(197)*	8*	1,003	0*	121*	0*	71	(15,300)*
Net change in cash	(8,341)*	(512)*	(40,331)	(31,462)*	(2,910)*	(13,593)*	(4,176)	(9,109)*	18,099*	10,701*	(5,039)	(19,913)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Aldeyra Therapeutics	45,090	not reported	(4,589)*	60.3M	9.8 quarters	Q2 FY26 10-QJun 30, 2026
Heron Therapeutics	20,721	not reported	(2,213)*	189.9M	19.3 quarters	Q2 FY26 10-QJun 30, 2026
Sagimet Biosciences	165,896	not reported	(11,099)*	not reported	21.6 quarters	Q2 FY26 10-QJun 30, 2026
Lifecore Biomedical	17,241	not reported	(2,189)*	37.9M	7.9 quarters	Q2 FY26 10-QJun 30, 2026
Annexon	199,270	not reported	(48,007)*	not reported	4.4 quarters	Q2 FY26 10-QJun 30, 2026
Precigen	16,329	54,978	(17,809)*	358.0M	2.1 quarters	Q2 FY26 10-QJun 30, 2026
SELLAS Life Sciences Group	138,343	not reported	(7,588)*	201.9M	18.2 quarters	Q2 FY26 10-QJun 30, 2026
DBV Technologies	165,700	1,600	(51,500)*	314.4M	3.2 quarters	Q3 FY26 10-QSep 30, 2026
Corvus Pharmaceuticals	18,905	not reported	(15,398)*	84.1M	14.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.